|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for TMPRSS2(NM_001135099.1) Search again
Powered by BiozBy default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Summary
This gene encodes a protein that belongs to the serine protease family. The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain. Serine proteases are known to be involved in many physiological and pathological processes. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue. The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq].
Gene References into function
- present study describes how TMPRSS2 may contribute to prostate tumour metastasis via the activation of PAR-2
- Data show the presence of the TMPRSS2/ERG gene fusion is common in prostate adenocarcinoma.
- Dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development.
- genomic microdeletion of chromosome 21 is associated with rearrangement, as shown by FISH analysis of TMPRSS2/ERG fusions in prostate cancer
- TMPRSS2 and HAT are candidates for proteolytic activation of influenza viruses in vivo
- demonstrate for the first time that the TMPRSS2-ERG fusion gene can be detected in a proportion of HGPIN lesions and that this molecular rearrangement is an early event that may precede chromosome-level alterations in prostate carcinogenesis
- Gene is deleted in gastric and colorectal cancers.
- findings show that the TMPRSS2-ERG fusion is common in prostate cancer and that the related TMPRSS2-ETV1 fusion is very rare; frequency of ERG-fusions in the present study is somewhat lower than previously observed
- TMPRSS2:ERG prostate cancer gene fusion may lead to haploinsufficiency or additional fusion events.
- TMPRSS2-ERV1 fusion protein was found in 1/82 prostate neoplasms. TMPRSS2-ERG fusion protein was found in 35/82 prostate neoplasms.
- presence/absence of Alu family consensus sequence in the introns of TMPRSS2 and ERG correlates with the presence/absence of fusion transcripts and indicates consensus sequence may be involved in prostate cancer
- Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma.
- Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer.
- A TMPRSS2:ETV5 gene fusion was identified in prostate cancer.
- further study is required to address association between TMPRSS2:ERG fusion and prostate cancer metastasis, detection of genomic truncation of the ERG gene could be useful for monitoring appearance of CTC and potential for prostate cancer metastasis
- Detection of ETS fusion gene by RT-PCR is feasible on formalin-fixed and paraffin-embedded samples.
- TMPRSS2-ERG with interstitial deletion is an aggressive and, in this study, uniformly lethal molecular subtype of prostate cancer associated with androgen-independent disease
- the detection of isolated TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia would improve the positive predictive value of finding TMPRSS2-ERG fusion prostate cancer in subsequent biopsies.
- The TMPRSS2:ERG rearrangement can be found in about one third of prostate cancers. A subgroup of prostate cancer patients with a good prognosis may be identified by the rearrangement
- Efficient multiplication of metapneumovirus in Vero cells expressing TMPRSS2 is reported.
- Information of TMPRSS2:ERG fusion status improved prognostification of the multigene model.
- analysis of the TMPRSS2-ERG splice variants in prostate cancer
- TMPRSS2-ERG gene fusion has a role in prostate cancer characteristics and outcomes
- TMPRSS2/ERG fusion isoforms have variable biological activities promoting tumor initiation and progression.
- Translocation of TMPRSS2-ERG is not associated with outcome and the aggressive clinical features associated with copy number increas in prostate cancer.